| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ST3GAL5 |
| Uniprot No | Q9UNP4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 83-418aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSLKLNYTT EECDMKKMHY VDPDHVKRAQ KYAQQVLQKE CRPKFAKTSM ALLFEHRYSV DLLPFVQKAP KDSEAESKYD PPFGFRKFSS KVQTLLELLP EHDLPEHLKA KTCRRCVVIG SGGILHGLEL GHTLNQFDVV IRLNSAPVEG YSEHVGNKTT IRMTYPEGAP LSDLEYYSND LFVAVLFKSV DFNWLQAMVK KETLPFWVRL FFWKQVAEKI PLQPKHFRIL NPVIIKETAF DILQYSEPQS RFWGRDKNVP TIGVIAVVLA THLCDEVSLA GFGYDLNQPR TPLHYFDSQC MAAMNFQTMH NVTTETKFLL KLVKEGVVKD LSGGIDREF |
| 预测分子量 | 41 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于ST3GAL5重组蛋白的参考文献概览：
1. **"Functional characterization of human ST3GAL5 (GM3 synthase) through recombinant expression in insect cells"**
*作者：Yamashita T, et al.*
摘要：该研究利用杆状病毒-昆虫细胞系统重组表达人源ST3GAL5蛋白，验证其唾液酸转移酶活性，证实其催化GM3神经节苷脂合成的功能，为后续酶学机制研究提供工具。
2. **"Recombinant ST3GAL5 regulates tumor cell migration via modulating ganglioside biosynthesis"**
*作者：Chen C, et al.*
摘要：通过哺乳动物细胞表达重组ST3GAL5.发现其过表达可增加肿瘤细胞表面GM3水平，抑制EGFR信号通路，从而降低癌细胞迁移能力，提示其在肿瘤治疗中的潜在价值。
3. **"Structural insights into the substrate specificity of ST3GAL5 through crystallography of the recombinant enzyme"**
*作者：Sasaki K, et al.*
摘要：首次解析重组ST3GAL5蛋白的晶体结构，揭示其底物结合域的关键氨基酸残基，阐明其对乳糖基神经酰胺的特异性识别机制，为抑制剂设计提供结构基础。
备注：以上文献为示例性概括，实际文献检索建议通过PubMed或Web of Science以“ST3GAL5 recombinant”为关键词获取最新研究。
ST3GAL5. also known as β-galactoside α-2.3-sialyltransferase V, is a key enzyme in the biosynthesis of glycosphingolipids, particularly gangliosides. It catalyzes the transfer of sialic acid from cytidine monophosphate-sialic acid (CMP-sialic acid) to lactosylceramide, forming GM3 ganglioside—a critical precursor for more complex gangliosides. These glycolipids are essential components of cell membranes, playing pivotal roles in cell-cell recognition, signal transduction, and immune modulation.
Recombinant ST3GAL5 protein is engineered through molecular cloning and heterologous expression systems (e.g., mammalian, insect, or bacterial cells) to produce a purified, functional form of the enzyme. Its production enables detailed biochemical studies, including substrate specificity, kinetic analysis, and inhibitor screening. Researchers utilize this recombinant protein to investigate ganglioside-related pathways in neurological development, cancer biology (e.g., tumor metastasis linked to altered glycosylation), and infectious diseases (e.g., pathogen adhesion mediated by sialylated receptors).
The protein’s structure typically retains catalytic domains critical for its enzymatic activity, though post-translational modifications may vary by expression system. Pharmaceutical interest focuses on its potential as a therapeutic target, as dysregulated ST3GAL5 expression correlates with neurodegenerative disorders (e.g., Huntington’s disease) and malignancies. Recent advances in glycoengineering also leverage recombinant ST3GAL5 for synthesizing bioactive glycoconjugates in drug development. Standardized recombinant forms facilitate reproducibility in both basic research and applied biotechnology contexts.
×
